文献速递肝病消化道肿瘤与早癌

2012至2017年全球慢性肝病负担变化:NAFLD影响日益显著

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.
PubMed 文献 · Hepatology · 2020-10-27

基于2017年全球疾病负担研究数据,评估2012至2017年慢性肝病(原发性肝癌和肝硬化)的全球发病率、死亡率和伤残调整生命年。病毒性肝炎仍是肝病死亡最常见原因,而NAFLD是肝病死亡和疾病负担增长最快的因素。

要点

  • 肝癌和肝硬化死亡中NAFLD分别占8%和9%,但NAFLD相关肝癌年龄标化死亡率年增1.42%。
  • 肝硬化年龄标化死亡率下降,但NAFLD相关肝硬化年龄标化死亡率年增0.29%。

核心结论

  • 2012至2017年全球肝癌和肝硬化负担增加,病毒性肝炎仍是肝病死亡最常见原因,NAFLD是肝病死亡和疾病负担增长最快的因素。

研究设计与样本

  • 基于2017年全球疾病负担研究的数据分析,评估2012至2017年慢性肝病(原发性肝癌和肝硬化)的全球发病率、死亡率和伤残调整生命年。

主要发现

  • 肝癌和肝硬化分别占肝病死亡的38.3%和61.7%;肝癌死亡中HBV占39%、HCV占29%、ALD占16%、NAFLD占8%,肝硬化死亡中HBV占29%、HCV占26%、ALD占25%、NAFLD占9%。
  • 2012至2017年,肝癌年龄标化发病率从11.1增至11.8/10万,年龄标化死亡率从10.1增至10.2/10万,年龄标化DALY率从250.4增至253.6/10万。
  • 肝硬化年龄标化发病率从66.0增至66.3/10万,年龄标化死亡率从17.1降至16.5/10万,年龄标化DALY率从532.9降至510.7/10万。
  • 肝癌年龄标化死亡率年变化百分比在东欧增幅最大(APC=2.18% [0.89%-3.49%]),在高收入亚太地区降幅最大(APC=-2.88% [-3.58至-2.18])。

关键数值与推荐

  • 肝癌-NAFLD年龄标化死亡率年增1.42%(1.00%-1.83%),肝癌-ALD年增0.53%(0.08-0.89),HBV(P=0.224)和HCV(P=0.054)无增加。
  • 肝硬化-NAFLD年龄标化死亡率年增0.29%(0.01%-0.59%),肝硬化-ALD年降0.44%(-0.78%至-0.40%),肝硬化-HCV年降0.50%(-0.81%至-0.18%),肝硬化-HBV年降1.43%(-1.71%至-0.40%)。

临床怎么用

  • 临床应关注NAFLD作为肝病死亡和疾病负担增长最快的原因,在肝癌和肝硬化管理中加强NAFLD相关筛查与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol-associated liver disease (ALD) are main causes of chronic liver disease. We assessed the global incidence, mortality, and disability-adjusted life-years (DALYs) related to chronic liver disease (primary liver cancer [LC] and cirrhosis). APPROACH AND RESULTS: We obtained data from the 2017 Global Burden of Disease study. In 2017, there were 2.14 million liver-related deaths (2.06-2.30 million), representing an 11.4% increase since 2012 (16.0% increase in LC deaths; 8.7% increase in cirrhosis deaths). LC and cirrhosis accounted for 38.3% and 61.7%, respectively, of liver deaths (LC and cirrhosis deaths were related to HBV [39% and 29%], HCV [29% and 26%], ALD [16% and 25%], and NAFLD [8% and 9%]). Between 2012 and 2017, age-standardized incidence rate, age-standardized death rate (ASDR), and age-standardized DALY rate increased for LC from 11.1 to 11.8, 10.1 to 10.2, and 250.4 to 253.6 per 100,000, respectively. Although age-standardized incidence rate for cirrhosis increased from 66.0 to 66.3, ASDR and age-standardized DALY rate decreased from 17.1 to 16.5 and 532.9 to 510.7, respectively. The largest increase in ASDR for LC occurred in Eastern Europe (annual percent change [APC] = 2.18% [0.89%-3.49%]), whereas the largest decrease occurred in high-income Asia Pacific (APC = -2.88% [-3.58 to -2.18%]). ASDR for LC-NAFLD and ALD increased annually by 1.42% (1.00%-1.83%) and 0.53% (0.08-0.89), respectively, whereas there were no increases for HBV (P = 0.224) and HCV (P = 0.054). ASDR for cirrhosis-NAFLD increased (APC = 0.29% [0.01%-0.59%]) but decreased for ALD (APC = -0.44% [-0.78% to -0.40%]), HCV (APC = -0.50% [-0.81% to -0.18%]), and HBV (APC = -1.43% [-1.71% to -0.40%]). CONCLUSIONS: From 2012 to 2017, the global burden of LC and cirrhosis has increased. Viral hepatitis remains the most common cause of liver deaths, and NAFLD is the most rapidly growing contributor to liver mortality and morbidity.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Paik JM, Golabi P, Younossi Y, et al. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020. PMID: 32043613. doi:10.1002/hep.31173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。